| Literature DB >> 29702549 |
Rania S Ali1,2, Hosam A Saad3,4.
Abstract
A novel fused system with three or four fused rings—pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-b][1,2,4,5]tetrazine and pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b]pyrimido[4,5-e][1,3,4]Entities:
Keywords: antitumor activity; biological applications; cyclization reactions; pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-b][1,2,4,5]tetrazine
Mesh:
Substances:
Year: 2018 PMID: 29702549 PMCID: PMC6099593 DOI: 10.3390/molecules23051024
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis and some reactions on 3-hydrazinyl-7-(thiophen-2-yl)pyridazino[3,4-e][1,2,4]triazin-4(6H)-amine.
Scheme 2Some reactions on 4(6H)-amino-3-hydrazinyl-7-(thiophen-2-yl)pyridazino[3,4-e][1,2,4]triazine.
Scheme 3Synthesis and some reactions of 3-amino-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine-8-carbonitrile.
Scheme 4The mechanism of formation of compound 15.
Scheme 5Some reactions of 3-amino-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine-8-carbonitrile.
Scheme 6Mechanism of cyclization of compound 16.
Scheme 7Some reactions of 9-amino-3-(2-thienyl)-2H,8H-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine-8-carbonitrile.
Scheme 8Mechanism of formation of compound 22.
Scheme 9Mechanism of formation of compound 23.
Figure 1The anti-tumor activities of the tested compounds expressed as IC50 values and compared with reference standard drugs evaluated on breast cancer, liver cancer, and colon carcinoma cell lines.
The anti-tumor activities of the tested compounds expressed as IC50 values and compared with reference standard drugs evaluated on breast cancer and liver cancer cell lines.
| Sample Code | MCF-7 | HepG-2 | HCT-116 |
|---|---|---|---|
| 2 | 29.6 ± 0.9 | 25 ± 0.4 | 30.9 ± 0.4 |
| 12 | 43.9 ± 1.2 | 28.6 ± 0.9 | 34.9 ± 0.6 |
| 3 | 54 ± 0.8 | 35.5 ± 1.2 | 46.2 ± 0.7 |
| 4 | 54.5 ± 1.2 | 30.2 ± 0.4 | 45.4 ± 0.8 |
| 5 | 168 ± 4.5 | 102 ± 0.9 | 160 ± 2.3 |
| 6 | 100 ± 0.9 | 30.7 ± 0.7 | 59.3 ± 0.8 |
| 7 | 78.2 ± 1.2 | 35.6 ± 0.9 | 59.5 ± 1.2 |
| 10 | 404 ± 3.4 | 206 ± 2.3 | 244 ± 3.9 |
| 16 | 29.2 ± 0.7 | 23.6 ± 0.6 | 27.4 ± 0.6 |
| Cisplatin | 5.71 ± 0.4 | 3.67 ± 0.2 | 2.43 ± 0.2 |